{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T12:24:47Z","timestamp":1794572687387,"version":"4.9.1"},"reference-count":28,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"10","license":[{"start":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T00:00:00Z","timestamp":1598486400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Secondary acute myeloid leukemia (sAML) after myelodysplastic or myeloproliferative disorders is a high-risk category currently identified by clinical history or specific morphological and cytogenetic abnormalities. However, in the absence of these features, uncertainties remain to identify the secondary nature of some cases otherwise defined as de novo AML. To test whether a chromatin-spliceosome (CS) mutational signature might better inform the definition of the de novo AML group, we analyzed a prospective cohort of 413 newly diagnosed AML patients enrolled into a randomized clinical trial (NILG AML 02\/06) and provided with accurate cytogenetic and molecular characterization. Among clinically defined de novo AML, 17.6% carried CS mutations (CS-AML) and showed clinical characteristics closer to sAML (older age, lower white blood cell counts and higher rate of multilineage dysplasia). Outcomes in this group were adverse, more similar to those of sAML as compared to de novo AML (overall survival, 30% in CS-AML and 17% in sAML vs 61% in de novo AML, P&lt;0.0001; disease free survival, 26% in CS-AML and 22% in sAML vs 54% of de novo AML, P&lt;0.001) and independently confirmed by multivariable analysis. Allogeneic transplant in first complete remission improved survival in both sAML and CS-AML patients. In conclusion, these findings highlight the clinical significance of identifying CS-AML for improved prognostic prediction and potential therapeutic implications. (NILG AML 02\/06: ClinicalTrials.gov Identifier: NCT00495287).<\/jats:p>","DOI":"10.3324\/haematol.2020.252825","type":"journal-article","created":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T13:20:40Z","timestamp":1598534440000},"page":"2578-2587","source":"Crossref","is-referenced-by-count":23,"title":["Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02\/06"],"prefix":"10.3324","volume":"106","author":[{"family":"Chiara Caprioli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Federico Lussana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Silvia Salmoiraghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Roberta Cavagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Ksenija Buklijas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Lara Elidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Pamela Zanghi'","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Anna Michelato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Federica Delaini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Elena Oldani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Tamara Intermesoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Anna Grassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Giacomo Gianfaldoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Francesco Mannelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Dario Ferrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Ernesta Audisio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Elisabetta Terruzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Lorella De Paoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Chiara Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Erika Borlenghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Irene Cavattoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Monica Tajana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Anna Maria Scattolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Daniele Mattei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Paolo Corradini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Leonardo Campiotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Fabio Ciceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Massimo Bernardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Elisabetta Todisco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Agostino Cortelezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Brunangelo Falini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Chiara Pavoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Renato Bassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Orietta Spinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Alessandro Rambaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2020,8,27]]},"reference":[{"key":"29714","doi-asserted-by":"crossref","unstructured":"Arber DA, Orazi A, Hasserjian R. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391-2405.","DOI":"10.1182\/blood-2016-03-643544"},{"key":"29715","doi-asserted-by":"crossref","unstructured":"Weinberg OK, Seetharam M, Ren L. Clinical characterization of acute myeloid leukemia with myel-odysplasia-related changes as defined by the 2008 WHO classification system. Blood. 2009; 113(9):1906-1908.","DOI":"10.1182\/blood-2008-10-182782"},{"key":"29716","doi-asserted-by":"crossref","unstructured":"Naqvi K, Jabbour E, Bueso-Ramos C. Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers. Blood. 2011; 118(17):4690-4693.","DOI":"10.1182\/blood-2011-03-342642"},{"key":"29717","doi-asserted-by":"crossref","unstructured":"Lancet JE, Uy GL, Cortes JE. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute mye-loid leukemia. J Clin Oncol. 2018; 36(26):2684-2692.","DOI":"10.1200\/JCO.2017.77.6112"},{"key":"29718","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Pratz K, Pullarkat V. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019; 133(1):7-17.","DOI":"10.1182\/blood-2018-08-868752"},{"key":"29719","doi-asserted-by":"crossref","unstructured":"D\u00f6hner H, Dolnik A, Tang L. Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care. Leukemia. 2018; 32(12):2546-2557.","DOI":"10.1038\/s41375-018-0257-z"},{"key":"29720","doi-asserted-by":"crossref","unstructured":"D\u00f6hner H, Estey E, Grimwade D. Diagnosis and management of AML in adults: 2017 ELN recom-mendations from an international expert panel. Blood. 2017; 129(4):424-447.","DOI":"10.1182\/blood-2016-08-733196"},{"key":"29721","doi-asserted-by":"crossref","unstructured":"de Witte T, Hagemeijer A, Suciu S. Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European intergroup trial. Haematologica. 2010; 95(10):1754-1761.","DOI":"10.3324\/haematol.2009.019182"},{"key":"29722","doi-asserted-by":"crossref","unstructured":"Lindsley RC, Mar BG, Mazzola E. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015; 125(9):1367-1376.","DOI":"10.1182\/blood-2014-11-610543"},{"key":"29723","doi-asserted-by":"crossref","unstructured":"Haferlach T, Nagata Y, Grossmann V. Landscape of genetic lesions in 944 patients with myelodys-plastic syndromes. Leukemia. 2014; 28(2):241-247.","DOI":"10.1038\/leu.2013.336"},{"key":"29724","doi-asserted-by":"crossref","unstructured":"Makishima H, Yoshizato T, Yoshida K. Dynamics of clonal evolution in myelodysplastic syndromes. Nat Genet. 2017; 49(2):204-212.","DOI":"10.1038\/ng.3742"},{"key":"29725","doi-asserted-by":"crossref","unstructured":"Vannucchi AM, Lasho TL, Guglielmelli P. Mutations and prognosis in primary myelofibrosis. Leu-kemia. 2013; 27(9):1861-1869.","DOI":"10.1038\/leu.2013.119"},{"key":"29726","doi-asserted-by":"crossref","unstructured":"Lasho TL, Mudireddy M, Finke CM. Targeted next-generation sequencing in blast phase myelopro-liferative neoplasms. Blood Adv. 2018; 2(4):370-380.","DOI":"10.1182\/bloodadvances.2018015875"},{"key":"29727","doi-asserted-by":"crossref","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016; 374(23):2209-2221.","DOI":"10.1056\/NEJMoa1516192"},{"key":"29728","doi-asserted-by":"crossref","unstructured":"Metzeler KH, Herold T, Rothenberg-Thurley M. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. Blood. 2016; 128(5):686-698.","DOI":"10.1182\/blood-2016-01-693879"},{"key":"29729","doi-asserted-by":"crossref","unstructured":"Dicker F, Haferlach C, Sundermann J. Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML. Leukemia. 2010; 24(8):1528-1532.","DOI":"10.1038\/leu.2010.124"},{"key":"29730","doi-asserted-by":"crossref","unstructured":"Bassan R, Intermesoli T, Masciulli A. Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML. Blood Adv. 2019; 3(7):1103-1117.","DOI":"10.1182\/bloodadvances.2018026625"},{"key":"29731","doi-asserted-by":"crossref","unstructured":"Salmoiraghi S, Cavagna R, Zangh\u00ec P. High throughput molecular characterization of normal karyo-type acute myeloid leukemia in the context of the prospective trial 02\/06 of the Northern Italy Leukemia Group (NILG). Cancers. 2020; 12(8):2242.","DOI":"10.3390\/cancers12082242"},{"key":"29732","doi-asserted-by":"crossref","unstructured":"Cheson BD, Bennett JM, Kopecky KJ. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003; 21(24):4642-4649.","DOI":"10.1200\/JCO.2003.04.036"},{"key":"29733","doi-asserted-by":"crossref","unstructured":"Levine RL, Valk PJM. Next-generation sequencing in the diagnosis and minimal residual disease as-sessment of acute myeloid leukemia. Haematologica. 2019; 104(5):868-871.","DOI":"10.3324\/haematol.2018.205955"},{"key":"29734","doi-asserted-by":"crossref","unstructured":"Papaemmanuil E, Gerstung M, Malcovati L. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013; 122(22):3616-3627.","DOI":"10.1182\/blood-2013-08-518886"},{"key":"29735","doi-asserted-by":"crossref","unstructured":"Ley TJ, Miller C, Ding L. Genomic and epigenomic landscapes of adult de novo acute myeloid leu-kemia. N Engl J Med. 2013; 368(22):2059-2074.","DOI":"10.1056\/NEJMoa1301689"},{"key":"29736","doi-asserted-by":"crossref","unstructured":"Gardin C, Pautas C, Fournier E. Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results. Blood Adv. 2020; 4(9):1942-1949.","DOI":"10.1182\/bloodadvances.2019001349"},{"key":"29737","doi-asserted-by":"crossref","unstructured":"Brierley CK, Steensma DP. Targeting spliceosome in the treatment of myelodysplastic syndromes and other myeloid neoplasms. Curr Hematol Malig Rep. 2016; 11(6):408-415.","DOI":"10.1007\/s11899-016-0344-z"},{"key":"29738","doi-asserted-by":"crossref","unstructured":"Steensma DP, Maris MB, Yang J. H3B- 8800.fig01-101: a first in human phase I study of a spliceosome modulator in patients with advanced myeloid malignancies. J Clin Oncol. 2017; 35(Suppl 15):TPS7075.","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS7075"},{"key":"29739","doi-asserted-by":"crossref","unstructured":"Daigle SR, Olhava EJ, Therkelsen CA. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell. 2011; 20(1):53-65.","DOI":"10.1016\/j.ccr.2011.06.009"},{"key":"29740","doi-asserted-by":"crossref","unstructured":"Stein EM, DiNardo CD, Pollyea DA. Enasidenib in mutant IDH2 relapsed or refractory acute mye-loid leukemia. Blood. 2017; 130(6):722-731.","DOI":"10.1182\/blood-2017-04-779405"},{"key":"29741","doi-asserted-by":"crossref","unstructured":"R\u00f6llig C, Kramer M, Schliemann C. Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?. Blood. 2020; 136(7):823-830.","DOI":"10.1182\/blood.2019004583"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/9920\/71514","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9920\/71515","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9920\/71514","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T09:58:04Z","timestamp":1794045484000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/9920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,27]]},"references-count":28,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2020.252825","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8,27]]}}}